Clinical Trials

  • Principal Investigator:

    Adam M. Brickman, PhD
    The purpose of this study is to better understand how vascular health affects your thinking abilities. We hope that these findings will ultimately lead to treatments aimed to reduce cognitive impairment and dementia. We are actively recruiting adults between the ages of 65 and 90 who note some decline in memory or thinking over the past 3 years and who are of African American, Hispanic/Latino, or European ancestry. You will be asked to return to the Columbia University Medical Center every 12 to 18 months for a total of 3 assessments. At each visit, you will be asked to complete a series of...
  • Principal Investigator:

    Rebecca Straus Farber, MD
    We need your help today to gather information about the experience of patients with autoimmune diseases of the central nervous system (multiple sclerosis (MS), neuromyelitis optica (NMO), and antiMOG associated disease (MOGAD)) in regards to COVID-19 vaccines. Because individuals with MS, NMO, and MOGAD were not included in the COVID-19 vaccine trials, we want to learn more about the experience of individuals with these autoimmune diseases and the vaccine. Because many patients with central nervous system autoimmune disease also take medications that affect the immune system, we want to find...
  • Principal Investigator:

    Thomas H. Brannagan III, MD
    This is a multicenter, Phase 2/3 study to Evaluate the Efficacy and Safety of Nipocalimab Administered to Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Adults 18 yrs old or greater at the time of signing the informed consent.
  • Principal Investigator:

    Philip L. De Jager, MD, PHD
    The Snapshot study aims to understand brain and spinal cord aging in healthy individuals and individuals with multiple sclerosis (MS). We aim to identify new tools that will help us to achieve successful brain aging in the general population and in people with an underlying autoimmune disease. A critical aspect of this study is that we are looking for individuals who are willing to donate their brain and spinal cord when they pass away; this will enable the investigators to understand which molecules in the brain made someone more or less likely to age successfully. The brains will be housed...
  • Principal Investigator:

    Sheng-Han Kuo, MD
    Why? By investigating individuals with SCA, we will gain valuable insights into the specific mechanisms through which the cerebellum participates in cognitive processes. Who? Healthy adults over the age of 18, who would like to participate as controls. What? Participation involves one clinic visit for 3-4 Hours, involving cognitive baseline measurements, an electroencephalography (EEG) and functional magnetic resonance imaging (fMRI) recording during which a decision-making two-step task will be performed. Cost to me? There is no cost involved for participating in the study. You will receive...
  • Principal Investigator:

    Philip L. De Jager, MD, PHD
    The Snapshot study aims to understand brain and spinal cord aging in healthy individuals and individuals with multiple sclerosis (MS). We aim to identify new tools that will help us to achieve successful brain aging in the general population and in people with an underlying autoimmune disease. A critical aspect of this study is that we are looking for individuals who are willing to donate their brain and spinal cord when they pass away; this will enable the investigators to understand which molecules in the brain made someone more or less likely to age successfully. The brains will be housed...
  • Principal Investigator:

    Philip L. De Jager, MD, PHD
    MS Genetics aims to better understand the genetic component of demyelinating diseases by doing genetic testing on blood samples of participants. This study involves a one-time blood draw and completion of questionnaires spread out over a couple of years in hopes to better understand the genes that makes one predisposed to Multiple Sclerosis and various other demyelinating diseases.
  • Principal Investigator:

    Christiane Reitz, MD, PhD
    We are recruiting families with members under the age of 65 who have dementia or are experiencing memory problems. Our initial screening can be completed in person or over the phone. The evaluation will take about 1 to 1.5 hours per person and includes a: 1. Blood sample (5 tablespoons) or saliva (1 teaspoon) collection: These blood samples will allow us to examine genes to identify causative mutations. 2. Brief Neuropsychological Assessment. 3. Medical History: A research physician will collect basic medical information on you and your family. This assessment will provide information on...
  • Principal Investigator:

    Sarah A. O'Shea, MD
    The DIMENSION Study is evaluating the safety and effect on cognitive symptoms of an investigational oral drug in adults with early Huntington's disease. Cognitive symptoms may include difficulty paying attention or trouble thinking through steps of an activity or complex problems. Symptoms may also include difficulty planning, remembering, and staying on task, impaired judgment, and difficulty multi-tasking. There will be an open-label extension (OLE) study, which is planned to begin later in 2022. Participants who are interested can speak to the study team. To be eligible for the study, you...
  • Principal Investigator:

    Thomas H. Brannagan III, MD
    To be in this study you must have Diabetic Peripheral Neuropathic (DPN) and be 18 years of age, inclusive, with the presence of bilateral pain in lower extremities due to DPN for at least 6 months prior to Screening and be in a stable regimen for the treatment of T1DM or T2DM for 3 months prior to Screening.

Pages